Author | Vincent J. Picozzi, MD

Articles

Today's Forecast for the Adjuvant Treatment of Pancreatic Cancer: Clear or Cloudy?

May 01, 2007

ByVincent J. Picozzi, MD

Despite attempted curative resection of localized adenocarcinoma of the pancreas, most patients experience a recurrence and die of their disease. The Gastrointestinal Tumor Study Group, European Organisation for Research and Treatment of Cancer, and European Study Group for Pancreatic Cancer trials have suggested the benefit of adjuvant therapy. However, the relatively few randomized trials available have not established a definite standard of care due to study limitations. Although these trials, and the recently published Charité Onkologie (CONKO)-001 trial, have shown a definite advantage of adjuvant chemotherapy, the most effective chemotherapy and the role of radiation therapy remain unclear. This review will discuss the data available from reported trials of adjuvant and neoadjuvant therapy in pancreatic cancer, address the issues leading to the ongoing controversies, and consider future directions for clinical trials.

Patterns of Chemotherapy Administration in Patients With Intermediate-Grade Non-Hodgkin’s Lymphoma

October 01, 2001

ByVincent J. Picozzi, MD|Brad L. Pohlman, MD|Vicki A. Morrison, MD|Grant D. Lawless, MD|Martin W. Lee, MD|Robert O. Kerr, MD|Jon M. Ford, PhD|David J. Delgado, PhD|Moshe Fridman, PhD|William B. Carter, PhD

Records from 653 patients treated between 1991 and 1998 in the Oncology Practice Patterns Study (OPPS) were analyzed to determine contemporary chemotherapy delivery patterns in patients with intermediate-grade non-